ArticlePloS one2025
Risk factors for Overweight/Obesity among people living with HIV on antiretroviral therapy: An ambidirectional cohort study at a tertiary health facility in Zambia.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundOverweight and obesity are major concerns among people living with HIV (PLWH), particularly those on integrase inhibitors, as they elevate the risk of cardiovascular diseases. However, longitudinal data on the burden and risk factors for overweight/obesity in sub-Saharan Africa (SSA) remain limited. This study aimed to estimate the incidence and identify factors associated with overweight and obesity among PLWH who switched to a dolutegravir (DTG)-based ART regimen at Livingstone University Teaching Hospital.
methodsWe enrolled 249 adults aged ≥18 years living with HIV on ART [non-nucleoside/nucleotide reverse transcriptase inhibitor (NNRTI) n = 174, protease inhibitor (PI) n = 21, and DTG n = 54] with a baseline body mass index (BMI) < 25 kg/m² between April 2019 and May 2020 and conducted a single follow-up assessment between December 2022 and June 2023. Participants were followed for a median of 43 months (interquartile range [IQR]: 42, 44). At follow-up, all participants were on a DTG-based regimen for a median time of 23 months (IQR: 19, 40). Demographic, clinical, and laboratory data were collected using a structured questionnaire. The primary outcome was overweight/obesity, defined as BMI ≥ 25 kg/ m2. Poisson regression with robust standard errors was used to determine risk factors for being overweight and obesity.
resultsThe median age was 44 years (interquartile range (IQR) 36, 51) at baseline, with the majority being female (59.4%, n = 148). Over a total follow-up of 871.5 person-years, 44 incident cases of overweight/obesity occurred, yielding a cumulative incidence of 17.7% (44/249) and an incidence rate of 5.05 per 100 person-years. Factors positively associated with the risk of being overweight/obesity included being married (adjusted incidence rate ratio [aIRR] 2.34; 95% CI 1.24, 4.40), lower baseline CD4 count (aIRR 4.13; 95% CI 1.41, 13.38) and higher waist circumference (WC) values (aIRR 1.07; 95% CI 1.03, 1.11). While older age was associated with a lower risk of overweight/obesity (aIRR 0.97; 95% CI 0.94, 0.99).
conclusionThe burden of overweight/obesity was high, and it was significantly driven by demographic, anthropometric, and immunological factors among our study participants. The findings suggest the importance of implementing targeted screening and management strategies for overweight and obesity, particularly among married individuals with higher WC values. Studies investigating the underlying mechanisms of excessive weight gain among PLWH on an integrase inhibitor-based regimen in resource-limited settings are warranted.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.